ASATE

Asate Therapeutics is a Swiss biotechnology company developing a next-generation RNA interference (RNAi) platform based on asymmetric siRNA (asiRNA) technology. This proprietary platform utilizes a unique RNA structure—a short antisense strand and a longer sense strand—to achieve potent gene silencing with reduced off-target effects and improved cellular delivery compared to conventional siRNA. The company is primarily focused on oncology, targeting "undruggable" transcription factors and other drivers of cancer progression. Headquartered in the Bio-Technopark Schlieren-Zurich, Asate aims to translate its innovative RNA architecture into a robust pipeline of precision medicines for solid tumors. By leveraging its specialized RNA design, the company seeks to address high unmet medical needs in patients with difficult-to-treat cancers.